Country

ULTHERAPY® AWARDED “BEST NONSURGICAL SKIN TIGHTENER” IN NEWBEAUTY’S ANNUAL BEAUTY CHOICE AWARDS. Ultherapy® Earns a Best of Beauty Award for the Third Year in a Row

Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group) announced today that Ultherapy® has been named “Best Nonsurgical Skin Tightener” in the 2016 Beauty Choice Awards. This is the 3rd consecutive year Ultherapy® has been recognized by NewBeauty readers and editors in their Beauty Choice Awards. Ultherapy® is the first and only treatment FDA-cleared to non-invasively lift the eyebrow, neck, and chin, and to improve lines and wrinkles on the décolletage.

“Our continued recognition by New Beauty magazine, one of the top authorities in aesthetics, is a testament to the results physicians and patients see with Ultherapy,” said Patrick Urban, Vice President and Head of the Merz Aesthetics Device Division. “Ultherapy continues to be the top choice for physicians looking for a non-invasive solution to lifting and tightening the skin of the eyebrow, neck, and under the chin, and improve fine lines and wrinkles on the décolletage area.”

The winners of NewBeauty’s annual Beauty Choice Awards are selected by readers, editors, and beauty professionals, who cast their votes throughout the year. A complete list of Beauty Choice Award winners is included in the Winter/Spring 2016 issue of NewBeauty, currently available on newsstands and online.

“In my practice, I continue to utilize Ultherapy as my go-to treatment option for patients looking for lifting and tightening around the brow, neck, and especially, under the chin. I also love Ultherapy for the fine lines and wrinkles on the décolletage. Ultherapy is an effective treatment that provides visible and predictable results; and most importantly, patients are satisfied with the changes they see with the treatment,” stated Dr. Doris Day, Board Certified Dermatologist and founder of Day Dermatology and Associates.

For full Ultherapy® product and safety information, visit: http://www.Ultherapy.com/IFU.

About Merz Aesthetics

Merz Aesthetics is a division of Merz North America, a specialty healthcare company that develops and commercializes treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. As part of the Merz Pharma Group of companies, our ambition is to become the most admired, trusted and innovative aesthetics and neurotoxin company. By developing products that improve patients’ health and help them to live better, feel better and look better, Merz will continue to make significant contributions to the well-being of individuals around the world. Merz Aesthetics provides a range of treatment options, including devices, injectables and skincare, that enable physicians to use Merz technologies to treat a variety of patients and concerns. For more information about Merz Aesthetics and their U.S. product portfolio, please visit www.merzusa.com.

Download File:
03.29.2016 [ 0 KB ]

Press Contact

Merz North America

Emily Browder
Corporate Communications

 

Phone: +1 919.582.8114

Merz in the Americas

Merz has a direct presence in six countries in the Americas, as well as a network of selected professional distribution partners in South and Central America and the Caribbean. Merz in the Americas is headquartered in Raleigh, North Carolina, and has facilities in Mesa, Arizona, Franksville, Wisconsin as well as offices in Toronto, Canada, Mexico City, Bogotá, Colombia, São Paolo, Brazil and Buenos Aires, Argentina.

Merz Worldwide

With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.

Media Contact – Global

Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com

Media Contact – North America

Merz North America, Inc.
Corporate Communications
Emily Browder
Phone: +1 919.582.8114
Email: Emily.Browder@merz.com